Abstract 342P
Background
This study aimed to assess breast cancer (BC) patients' knowledge and perception of fertility risks and preservation, and to determine factors that impact fertility preservation(FP) patient decision making.
Methods
We performed a cross-sectional study including 70 BC patients ≤ 45 year-old. Patients were surveyed using a 29 item questionnaire assessing their personal experience and knowledge about fertility risks and FP treatments. A knowledge score (0-12) was calculated with 1 point awarded for each correct answer. Statistical associations between socio-demographic characteristics, personal experience and knowledge score were analyzed.
Results
Mean age was 34 year-old. Thirty-seven patients had a college degree and 80% were married. Previous pregnancy/live birth were reported in 77%/72% of patients. Twenty-seven percent of patients had prior contact with infertility. Fifty-five patients were informed about infertility risks related to BC treatment. Only 62.8% of patients received information about FP treatments. Thirty-five patients were referred to FP consultation of whom 12 patients received FP treatments. Embryos/oocytes freezing were the main used options. The main reasons for skipping FP treatments were lack of pregnancy desire (38.6%) and insufficient provided information (30%). “Complexity of FP procedure” and “fear of delaying cancer treatment” were reported in 8.6% and 4.3% of cases respectively. Mean knowledge score was 6(3 -11). Forty-six percent of patients believed that “FP treatment is related to an increased risk of cancer recurrence”. Only 61.4% of patients were aware that “freezed eggs remain available in the future whenever the patient is ready to use them”. Most of the patients (81.4%) were aware that having a spouse was not a prerequisite for FP treatment. Knowledge about FP treatments availability and costs was poor with more than half of patients overestimating costs and assuming the lack of FP treatment options. Only 60% of patients were aware of an operational legal framework for FP in Tunisia.
Conclusions
This study showed that FP baseline knowledge in BC patients is generally poor. Patient's access to clear and concise fertility information is the key for effective interventions for fertility preservation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
Presenter: Kevin Kalinsky
Session: Poster session 03
394P - CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
Presenter: Francesco Pantano
Session: Poster session 03
395P - Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Kyung Jung
Session: Poster session 03
396P - Real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer (mTNBC) in the United States (US)
Presenter: Kevin Punie
Session: Poster session 03
398P - A phase Ib/II study of IN10018/FAKi in combination with pegylated liposomal doxorubicin (PLD) and toripalimab in metastatic triple-negative breast cancer (TNBC): IN10018-010
Presenter: Xichun Hu
Session: Poster session 03
399P - Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC)
Presenter: weina shen
Session: Poster session 03
400P - The impact of CDK4/6 inhibitors on bone health: An Italian real-world experience
Presenter: Roberta Scafetta
Session: Poster session 03
401P - Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer with brain metastasis (UTOBIA-BM): A prospective, single-arm, phase II trial
Presenter: Yehui Shi
Session: Poster session 03
402P - First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study
Presenter: Hamdy Azim
Session: Poster session 03